Syros Pharmaceuticals (SYRS) Stock Statistics & Valuation Metrics

Syros Pharmaceuticals has a market cap or net worth of $684.23K. The enterprise value is ―.

Syros Pharmaceuticals has 26,832,457 shares outstanding. The number of shares has decreased by -2.65% in one year.

Syros Pharmaceuticals’s return on equity (ROE) is ― and return on invested capital (ROIC) is ―.

The current PE Ratio of Syros Pharmaceuticals is ―. Syros Pharmaceuticals’s PEG ratio is ―.

In the last 12 months, Syros Pharmaceuticals had revenue of 9.94M and earned -164.57M in profits. Earnings per share was -5.81.

In the last 12 months, operating cash flow was -100.02M and capital expenditures -38.00K, giving a free cash flow of -100.06M billion.

Syros Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―

Syros Pharmaceuticals upcoming earnings date is Jul 31, 2025, TBA Not Confirmed.

Syros Pharmaceuticals as a current ratio of ―, with Debt / Equity ratio of ―

In the past 12 months, Syros Pharmaceuticals has paid 0.00 in taxes.

Syros Pharmaceuticals EV to EBITDA ratio is ―, with an EV/FCF ratio of ―.

Syros Pharmaceuticals has $58.27M in cash and marketable securities with $60.23M in debt, giving a net cash position of $1.95M billion.

Gross margin is ―, with operating margin of ―, and net profit margin of ―.

The average price target for Syros Pharmaceuticals is $1.00, which is 11.43% higher than the current price. The consensus rating is Hold